Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton ...
Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia. Video, 00:03:33Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia ...
Its flagship product, Firdapse (amifampridine), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and children aged six and older. The company also markets Fycompa ...
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback